Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT03637803
Title MRx0518 and Pembrolizumab Combination Study
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors 4DPharma PLC


lung non-small cell carcinoma

renal cell carcinoma

urinary bladder cancer


MRx0518 + Pembrolizumab

Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
University of Kansas Medical Center Kansas City Kansas 66160 United States Details
UPMC Hillman Cancer Center Pittsburgh Pennsylvania 15232 United States Details
Houston Methodist Cancer Center Houston Texas 77030 United States Details
MD Anderson Cancer Center Houston Texas 77030 United States Details
Summit Cancer Center Spokane Washington 99208 United States Details
*Shaded cells indicate that there was no data available from for the field